Biolab Sanus Farmaceutica

biolabfarma.com

Biolab is one of the 10 largest pharmaceutical companies in Brazil. The main characteristics about the trajectory is based on the commitment to offer health and quality of life to the Brazilian population. It is a market leader in Cardiology medicine prescriptions, vice-leader in the segment of Gynecology and acts with relevance in the areas of Dermatology, Orthopedics, Rheumatology and Pediatrics. With a portfolio of more than 100 products, Biolab has one of the most modern Research, Development and Innovation (R&D) Centers in Brazil and is growing as a result of partnerships with universities and national and international research laboratories, as well as commitment with actions of social responsibility and support to Brazilian culture.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

DIGITAL & DOCUMENTATION TRANSFORMATION KEY TO PHARMA, MANUFACTURING AND ENERGY SURVIVAL AMIDST COVID-19

Sdcexec | April 28, 2020

news image

Last week, the U.S. energy sector faced a severe blow as the value of oil to be delivered in May dropped to a staggering -$37.60 per barrel—the first negative close in history. Pharma and manufacturing industries are facing similar wake-up calls for a future riddled with uncertainty. But the key to maintaining operations during and after the coronavirus crisis revolves around digital transformation and document management for processes, analytics, and an agile workforce, according to Brian...

Read More

BUSINESS INSIGHTS

SINORDA BIOMEDICINE AND PORTON ADVANCED TO FAST-TRACK THE DEVELOPMENT OF CELL THERAPIES FOR SOLID TUMORS

Porton Advanced | April 25, 2022

news image

Suzhou Porton Advanced Solutions Ltd. and Guizhou Sinorda Biomedicine Co. Ltd. announced a long-term strategic relationship in cell and gene therapy research and development and platform development. Porton Advanced provides plasmids, cell therapy, gene therapy, oncolytic virus, mRNA treatment, and bacterial therapy as part of an end-to-end gene and cell therapy CDMO service platform. Sinorda Biomedicine focuses on the R&D of revolutionary drugs for digestive tract disorders, ...

Read More

PHARMA TECH

WINHEALTH AND IMMEDICA ENTER INTO AN AGREEMENT THAT GIVES WINHEALTH THE RIGHTS TO RAVICTI® IN CHINA AND SEVERAL OTHER ASIA-PACIFIC COUNTRIES

WinHealth | January 04, 2021

news image

Hong Kong WinHealth Pharma Group Co., Ltd. furthermore, Immedica Pharma AB, today declared that they have gone into an understanding under which WinHealth has the restrictive business rights to Ravicti® (Glycerol Phenylbutyrate) for Greater China, South Korea, Singapore, Vietnam , Indonesia, Malaysia , the Philippines and Thailand gets. Ravicti® is shown for the treatment of urea cycle issue (UCD) in Europe and North America, and as a feature of the reported association, W...

Read More

BUSINESS INSIGHTS

MISSION BIO ANNOUNCES PHARMA ASSAY DEVELOPMENT SERVICES FOR SOLID TUMOR RESEARCH

Mission Bio | July 13, 2022

news image

Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced the launch of solid tumor assays through its Pharma Assay Development services. The availability of this new service offering will help to accelerate the development of cancer therapeutics by reducing the time and cost associated with the characterization of solid tumor cells. Precision therapeutics for solid tumors have been historically bottlenecked due to technical challenges a...

Read More
news image

DIGITAL & DOCUMENTATION TRANSFORMATION KEY TO PHARMA, MANUFACTURING AND ENERGY SURVIVAL AMIDST COVID-19

Sdcexec | April 28, 2020

Last week, the U.S. energy sector faced a severe blow as the value of oil to be delivered in May dropped to a staggering -$37.60 per barrel—the first negative close in history. Pharma and manufacturing industries are facing similar wake-up calls for a future riddled with uncertainty. But the key to maintaining operations during and after the coronavirus crisis revolves around digital transformation and document management for processes, analytics, and an agile workforce, according to Brian...

Read More
news image

BUSINESS INSIGHTS

SINORDA BIOMEDICINE AND PORTON ADVANCED TO FAST-TRACK THE DEVELOPMENT OF CELL THERAPIES FOR SOLID TUMORS

Porton Advanced | April 25, 2022

Suzhou Porton Advanced Solutions Ltd. and Guizhou Sinorda Biomedicine Co. Ltd. announced a long-term strategic relationship in cell and gene therapy research and development and platform development. Porton Advanced provides plasmids, cell therapy, gene therapy, oncolytic virus, mRNA treatment, and bacterial therapy as part of an end-to-end gene and cell therapy CDMO service platform. Sinorda Biomedicine focuses on the R&D of revolutionary drugs for digestive tract disorders, ...

Read More
news image

PHARMA TECH

WINHEALTH AND IMMEDICA ENTER INTO AN AGREEMENT THAT GIVES WINHEALTH THE RIGHTS TO RAVICTI® IN CHINA AND SEVERAL OTHER ASIA-PACIFIC COUNTRIES

WinHealth | January 04, 2021

Hong Kong WinHealth Pharma Group Co., Ltd. furthermore, Immedica Pharma AB, today declared that they have gone into an understanding under which WinHealth has the restrictive business rights to Ravicti® (Glycerol Phenylbutyrate) for Greater China, South Korea, Singapore, Vietnam , Indonesia, Malaysia , the Philippines and Thailand gets. Ravicti® is shown for the treatment of urea cycle issue (UCD) in Europe and North America, and as a feature of the reported association, W...

Read More
news image

BUSINESS INSIGHTS

MISSION BIO ANNOUNCES PHARMA ASSAY DEVELOPMENT SERVICES FOR SOLID TUMOR RESEARCH

Mission Bio | July 13, 2022

Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced the launch of solid tumor assays through its Pharma Assay Development services. The availability of this new service offering will help to accelerate the development of cancer therapeutics by reducing the time and cost associated with the characterization of solid tumor cells. Precision therapeutics for solid tumors have been historically bottlenecked due to technical challenges a...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us